Lights Out for Insomnia: New Kanabo Research Study Offers Encouraging Results

Tel Aviv, Israel (ots/PRNewswire) -

Kanabo Research (http://www.kanaboresearch.com) is proud to
present the promising results of its pre-clinical trial, which brings
the company one step closer to providing a safe remedy for insomnia
and other sleep disorders, without the risk of dependency or the
possibility of an overdose.

(Photo: https://mma.prnewswire.com/media/814939/Kanabo_Formulation
s_Infographic.jpg )

This in vivo study, evaluated the efficacy of varying compositions
of active ingredients in cannabis to induce sleep, in comparison to
Diazepam, the active ingredient in Valium.

Several formulations performed extremely well, reaching close to
100% of the efficacy of Diazepam, with one formulation in particular
increasing sleep duration by 150%. Kanabo Research
(http://www.kanaboresearch.com) was able to prove synergy, with
greater efficacy when all three cannabinoids and terpenes were
present than when used singularly. When combined, even a small amount
of each contributed to the efficacy of the formulation.

As a secondary finding, the study established the value of THC as
an integral part of Kanabo Research (http://www.kanaboresearch.com)'s
formulations. Even in small doses, THC generates a synergistic effect
with other cannabinoids and terpenes. This emphasizes and reiterates
the value of the whole plant profile, especially when compared to
isolates of cannabinoids. These are promising results for patients in
light of the well documented much less severe side effects associated
with low THC compositions in comparison to Diazepam.

These early findings are promising and will be applied to the next
stage of research - clinical trials for human use. Kanabo Research
(http://www.kanaboresearch.com) is currently in the process of
establishing the framework for such a study, and aims to perform the
trials and report on successful results by the end of the year.

The significance of such reliable, reputable scientific research,
as a means of establishing cannabis' status as a legitimate medicine
cannot be underestimated. Cannabis has evolved into a lucrative
revenue stream for investors and a powerful new weapon in the war
against multiple chronic disorders.

Up to now, those suffering from sleep disorders have had to rely
on habit forming conventional medications such as Valium and Ambien
that require the user to gradually increase the dose over time, often
resulting in dependency. These medications can have adverse effects,
including the risk of a lethal overdose. A safer alternative would be
a game-changer for sleep disorder sufferers.

Avihu Tamir, Kanabo Research's Founder and CEO noted, "While we
are only in the preliminary stages of our research, the results of
our pre-clinical trials are extremely encouraging for millions of
sleep disorder sufferers around the globe."

An estimated 70 million Americans have insomnia, and a further 43
million suffer from obstructive sleep apnea (OSA). According to P&S
Market Research, the sleeping aids market is set to be worth of
$101.9 billion by 2023.

Tamir continues: "We are in the process of developing two product
lines, one requiring a medical cannabis prescription, and the other,
an over the counter product that does not contain THC. We have only
scratched the surface of the full medicinal potential of cannabis and
as Kanabo Research mines this valuable resource, we hope to provide
safe alternatives to conventional medications for those suffering
from a wide variety of conditions. "

About Kanabo Research

Kanabo Research, an R&D company based in Israel, creates
innovative solutions for the medical cannabis industry. Kanabo
focuses on building medically validated IP that includes delivery
systems working in synergy with applications of patented formulations
of cannabis oil.

Website: http://www.kanaboresearch.com/

ots Originaltext: Kanabo Research
Im Internet recherchierbar: http://www.presseportal.de

Contact:
David Sack
David@kanaboresearch.com
+972-58-332-4826

Original-Content von: Kanabo Research, übermittelt durch news aktuell